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The Society for Maternal-Fetal Medicine (SMFM) continues to recommend that all women with a 20 history of a previous spontaneous preterm birth (PTB) of a singleton pregnancy be offered 17-alpha 21 hydroxyprogesterone caproate (17-OHPC) therapy in a subsequent pregnancy with a singleton gestation. 1 Data 22 from several sources suggest that despite these recommendations, there remains continued underutilization of 23 17-OHPC for eligible patients.
2-5 The purpose of this statement is to reaffirm the choice of progestogen for 24 women with a singleton gestation and a prior spontaneous PTB. 25
In 2003, Meis and colleagues reported the results of a multi-center double-masked randomized 26 controlled trial (RCT) involving 463 women with a singleton pregnancy and prior spontaneous PTB who 27 received 17-OHPC or placebo. 6 They found a 34% reduction in the incidence of recurrent PTB < 37 weeks of 28 gestation with 17-OHPC treatment (from 54.9% to 36.3%). The study was stopped early based on pre-specified 29 criteria due to findings at the second interim analysis (70% of planned sample were analyzed). The RCT 30 demonstrated significant reductions in both overall PTB and PTB <32 and <35 weeks of gestation, as well as 31 significant reductions in infant complications (IVH, NEC, and need for supplemental oxygen) in those receiving 32 17-OHPC. In the same year, da Fonseca and colleagues reported the findings of a double-masked RCT of 142 33 women at high-risk for PTB (94% had a prior PTB) who received either 100 mg vaginal progesterone per day 34 or placebo. 7 This study reported a reduction in the incidence of PTB < 37 weeks of gestation (28.5% to 13.8%, 35 p=0.03) and < 34 weeks of gestation (18.6% to 2.7%, p=0.002). 36
Initial guidance from the American College of Obstetricians and Gynecologist (ACOG) and SMFM 37 recommended treatment with either 17-OHPC or vaginal progesterone for women with a previous spontaneous 38 PTB to prevent recurrent PTB (2003, 2008) . 8 In addition, both prior to and after FDA approval of 17OHPC, 39 due to issues with access (e.g. cost, availability, insurance coverage), some experts argued for preferred use of 40 vaginal progesterone and many clinicians had no other options for their patients. 12 Moreover, data from the OPPTIMUM Study 59 published in 2016 by Norman and colleagues are consistent with these other trials and support the rationale for 60 the change in SMFM guidance. The OPPTIMUM study was a large (N= 1,228) multi-center double-masked 61 RCT comparing 200 mg vaginal progesterone per day vs. placebo in women at high-risk for PTB. 13 In subgroup 62 of women a history of prior spontaneous PTB (n=903), there were no differences in the rate of PTB weeks of 63 gestation between those receiving vaginal progesterone and placebo (15.9% vs 18.8%). A systematic review 64 and meta-analysis published by Romero and colleagues in 2016 that included data from the OPPTIMUM 65 reported a decrease in PTB < 34 weeks of gestation or fetal death (pooled RR 0.66, 95% CI 0.52-0.83]) with 66 vaginal progesterone vs. placebo for women with a sonographically short cervix < 25 mm. However, they did 67 not report outcomes for the subgroup of women with a history of prior spontaneous PTB. In summary, the 68 reasoning that vaginal progesterone has not been adequately proven to decrease recurrent PTB in women with aM A N U S C R I P T
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history of prior spontaneous PTB is based on the consistency of lack of benefit across multiple RCT's despite 70 heterogeneity of patient populations, clinical criteria, and progesterone dosing. However, SMFM continues to 71 affirm the use of vaginal progesterone to prevent preterm birth in women with sonographically short cervix < 72 20mm without a history of prior spontaneous PTB.
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Owen and colleagues performed an RCT involving cervical cerclage in women with a prior spontaneous 74 PTB < 34 weeks of gestation, and noted that approximately 69% of those with serial cervical length screening 75 had cervical length that remained > 25 mm.
14 A secondary analysis of this same RCT did not demonstrate any 76 additional benefit of 17-OHPC in women who received a cerclage for cervical shortening. In women with a 77 prior spontaneous PTB who start 17-OHPC therapy and then develop cervical shortening, it remains unknown 78 whether there is any benefit to change progestogen choice to vaginal progesterone (with or without cervical 79 cerclage placement). 15 Based on available data regarding the lack of benefit of vaginal progesterone in women 80 with a history of prior spontaneous PTB, we recommend continuation of 17-OHPC therapy in women with 81 history of prior spontaneous PTB throughout the pregnancy despite the development of cervical shortening 82 (with or without cervical cerclage placement). 83
Few studies directly compare 17-OHPC and vaginal progesterone in women with a history of prior 84 spontaneous PTB.
16-18 A recent meta-analysis reported outcomes for three trials that included a total of 680 85 women. 19 The largest study to directly compare 17-OHPC and vaginal progesterone was conducted in Saudi 86
Arabia and published in 2013 (this study accounts for 74% subjects in the meta-analysis). 18 In this study, 520 87 women with a history of one or more mid-trimester PTB or history of cervical cerclage in a prior pregnancy 88 were randomized to receive either 17-OHPC or vaginal progesterone; women receiving vaginal progesterone 89 were less likely to deliver < 34 weeks of gestation than those receiving 17-OHPC (16.6% vs. 25.7%, OR 0.58, 90 95% CI 0.37-0.89, p=0.02) but not < 37 weeks of gestation (32.8% vs 35.3%). Enrollment in this study 91 focused on a heterogeneous group of women with a cervical insufficiency phenotype (prior mid-trimester 92 preterm birth or cerclage), rather than the typical candidate for 17-OHPC in the US. Given the significant 93 differences in study population, eligibility criteria and study protocol, we believe this RCT is not generalizable 94 to women with a prior spontaneous PTB in the US. 
